Duffy Sean P. sold $357K of OMDA

Duffy Sean P. (Chief Executive Officer) sold 17,258 shares of Omada Health, Inc. (OMDA) at an average of $20.68 ($20.61–$20.90, $0.36M total) across 2 trades on 2026-10-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Duffy Sean P.
Published Oct 5, 2026, 9:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 5, 2026, 9:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$OMDA
Bearish
medium confidence
Mentioned
$OMDA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$OMDABearishLow
01

Why it matters

The transaction reduces the CEO's ownership and may be read as a bearish signal, though the size is modest.

02

Market read

A small insider sell that could cause modest short‑term pressure on OMDA shares.

03

What to watch

Recent positive earnings or product updates may offset the negative perception of the insider sale.

Relevance 3/10Novelty 3/10Timing: today

Background

Form 4 filing disclosed the CEO's sale of shares under a pre‑arranged 10b5-1 plan.

Company-level read

Ticker impact

$OMDABearishMedium confidence
Context

CEO Sean Duffy sold 17,258 shares for $356,915 via a 10b5-1 plan, reducing his stake to 382,594 shares.

Expected impact

likely slight downward pressure as the market prices in the insider sell

Evidence & confidence

Insider sales, even pre‑arranged, are often interpreted as a negative signal, especially when the CEO reduces a sizable position.

Market effects

Minimal impact on the digital health sector; the sale is company‑specific.

No broader regional effect; confined to Omada Health investors.

Negligible on a global scale.

Counterpoint

The sale could be purely portfolio rebalancing under a 10b5-1 plan, not a lack of confidence.

Key entities

  • Omada Health, Inc.

    Digital health platform listed on Nasdaq under ticker OMDA.

  • Sean Duffy

    Chief Executive Officer of Omada Health.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$OMDAHigh

Omada Health Earnings Call Signals Strong Growth Ahead

Omada Health (OMDA) reported Q3 revenue of $91M, up 34% YoY, with GAAP net income of $7M vs. a loss last year. Adjusted EBITDA rose to $12M. Management raised 2026 revenue guidance to $344M-$346M and adjusted EBITDA to $32M-$34M, citing strong demand for diabetes and hypertension programs. The company expects Q4 seasonality and GLP-1 coverage uncertainty.

$OMDAMed

What Omada Health (OMDA) Said on Its Q3 Earnings Call

Omada Health (OMDA) expects Q4 revenue to decline due to seasonal factors, with adjusted EBITDA also moderating. The company ended Q3 with $243M in cash and no debt. CEO Sean Duffy will transition to executive chair in 2027, with Shao taking over as CEO. Omada's GLP-1 Care Track showed a 6% average weight loss at 12 weeks, according to peer-reviewed research.

$OMDAMedAI 8/10

Omada Health Inc (OMDA) (Q3 2026) Earnings Call Highlights: Record Revenue, Membership

Omada Health Inc (OMDA) reported record revenue and membership growth in Q3 2026. However, new enrollments are expected to decline in Q4 due to seasonality and tough comparisons. GLP-1 market dynamics and rising healthcare costs create uncertainty for 2027. Adjusted EBITDA is expected to moderate due to increased R&D and staffing. The company aims for 20%+ growth in 2027 through expanding covered lives, improving enrollment rates, and increasing engagement.